Search Results
Your search for AT matches 29621 pages
Showing 18201 - 18250Atezolizumab: Another Therapeutic Option for Patients With Previously Treated Non–Small Cell Lung Cancer
The OAK study—recently reported by Rittmeyer and colleagues and reviewed in this issue of The ASCO Post—is the first study to show patients with previously treated non–small cell lung cancer (NSCLC) treated with a humanized antibody (atezolizumab, Tecentriq) directed against the programmed cell...
Atezolizumab Improves Overall Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer
In the phase III OAK trial reported in The Lancet by Achim Rittmeyer, MD, of Lungenfachklinik Immenhausen, Germany, and colleagues, treatment with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) improved overall survival vs docetaxel in previously treated non–small ...
Autologous Transplantation for Myeloma: Don’t Change the Winning Team
Over the past 20 years, the Intergroupe Francophone du Myelome (IFM) and Dr. Michel Attal have pioneered the use of autologous hematopoietic cell transplantation (AHCT) for multiple myeloma in a series of randomized studies. Notable studies include comparisons of planned upfront AHCT vs...
Lenalidomide, Bortezomib, and Dexamethasone With or Without Transplantation in Younger Myeloma Patients
In the French phase III IFM 2009 trial reported in The New England Journal of Medicine by Michel Attal, MD, of the Institut Universitaire du Cancer de Toulouse-Oncopole, and colleagues, consolidation treatment with lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) was...
Brian Marr, MD, Joins Division of Ophthalmic Oncology at NewYork-Presbyterian/Columbia University Medical Center
Brian Marr, MD, has joined the Department of Ophthalmology at NewYork-Presbyterian/Columbia University Medical Center as Director of the Division of Ophthalmic Oncology. He will also serve as Professor of Ophthalmology at Columbia University Medical Center. With Dr. Marr’s arrival,...
Brian Wolpin, MD, MPH, Named Director of Gastrointestinal Cancer Center at Dana-Farber
Brian Wolpin, MD, MPH, has been named the new Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute. Dr. Wolpin is Associate Professor of Medicine at Harvard Medical School and was appointed earlier this year as the Robert T. and Judith B. Hale Chair in Pancreatic Cancer...
Combinations of Novel Treatment Approaches Continue to Make Progress in Overcoming Challenges of Pediatric Brain Tumors
Nearly 2,500 children in the United States are diagnosed with brain tumors each year, making these malignancies among the most common solid tumors in children and adolescents. Despite advances over the past few decades, the treatment of brain tumors remains one of the most challenging clinical...
Geriatric Oncology: A Multidisciplinary Approach in a Global Environment
Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and Professor of...
ASCO Launches Volunteer Corps
ASCO is very fortunate to have an active member base eager to volunteer, share expertise, and give back to the oncology community. Currently, more than 2,000 volunteers are engaged on ASCO committees, subcommittees, working groups, panels, task forces, editorial boards, and in various training...
Proposed Categories of Cancer Survivors Aim to Bring Survivorship Into Precision Medicine Era
Care for people who have survived or are living with cancer should acknowledge the heterogeneity of their needs and experiences and should reflect the same level of personalization that is now guiding active cancer therapy. At a time when more people are surviving cancer than ever before, new...
Help Your Patients Catch Up on the Latest Research From the 2017 ASCO Annual Meeting
On the Cancer.Net blog (www.cancer.net/blog), your patients can learn about the research highlighted at the 2017 ASCO Annual Meeting, including what it means for their care and treatment. They can also follow the blog for additional updates from the Meeting, including podcasts with ASCO experts...
ASCO Resources Help Practices Navigate Quality Reporting Under MACRA
The Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA), launched this January and is being implemented in oncology practices across the country. In 2017, practices must report some quality data in order to avoid financial penalties in 2019. ASCO...
Wendy S. Rubinstein, MD, PhD, FACMG, FACP, Joins CancerLinQ LLC as Division Director, Clinical Data Management and Curation
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has -announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Dr. Rubinstein will oversee the team working to securely process and analyze the -CancerLinQ®...
Combination Therapy With Pembrolizumab in Metastatic Nonsquamous NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 10, 2017, pembrolizumab (Keytruda) was granted accelerated...
Selected Novel Agents in Development for Multiple Myeloma
Here are several abstracts selected from the proceedings of the 2016 America Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics for the development for patients with relapsed or refractory multiple myeloma. For full details of these study abstracts, visit...
Targeting the Androgen Receptor in Breast Cancer
One of the most active areas of research in breast cancer involves the targeting of the androgen receptor. Trials underway for androgen receptor antagonists and modulators, alone and in various combinations of available agents and novel therapies, are yielding encouraging early results. At the 2017 ...
Expert Point of View: Michael Berry, MD
Michael Berry, MD, a breast surgeon who is Director of the Margaret West Comprehensive Breast Center at The West Cancer Center, Memphis, told the The ASCO Post that these findings “echo what surgeons already know,” which is that lymphedema is a result of multiple insults to the axilla. But one...
Lymphedema Risk: It’s Not Just About the Surgery
In a study from the Mayo Clinic, Rochester, Minnesota, the risk of lymphedema in a population-based breast cancer cohort was related to multimodality therapy and not axillary surgery alone, investigators reported at the American Society of Breast Surgeons (ASBrS) Annual Meeting.1 “Most patients...
Elizabeth R. Plimack, MD, on Advanced Urothelial Cancer: Expert Perspective
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annual Meeting. (Abstracts 4501, 4503, 106)
Optimizing Quality of Life in Head and Neck Cancer Survivors
Head and neck cancer can take away a patient’s “right to feel human,” and its impact on physical appearance, physical functioning, and general quality of life can be devastating, according to Merry Sebelik, MD, Associate Professor of Head and Neck Surgery at Emory University in Atlanta. At a...
Proton Therapy Associated With Fewer Sequelae in the Treatment of Head and Neck Cancer
Radiation oncology is vital to the management of patients with cancer of the head and neck, and for certain patients, proton therapy may offer significant benefit over intensity-modulated radiation therapy, according to Walter J. Curran, MD, Executive Director of the Winship Cancer Institute of...
Targeted Therapy in the Age of Immunotherapy in Head and Neck Cancer
The impact of targeted therapies in head and neck cancer has been limited, but we can strategize to integrate the development of targeted and immunotherapeutic agents, according to Christine H. Chung, MD, Senior Member and Chair in the Department of Head and Neck-Endocrine Oncology at Moffitt...
New Horizons in Immunotherapy for Head and Neck Cancer
Immunotherapy is a new treatment paradigm in recurrent metastatic head and neck cancer, according to Nabil F. Saba, MD. At a symposium hosted by the Winship Cancer Institute and Emory University—Updates in the Management of Head and Neck Cancer—Dr. Saba discussed current research and new...
Lack of Access to Transfusions Limits Hospice Use by Patients With Hematologic Malignancies
A new survey finds that doctors would refer more patients with incurable blood cancers to hospice for end-of-life care if they could receive transfusions, which are generally not available because of hospice reimbursement policies. The findings, published by Oreofe Odejide, MD, MPH, and colleagues ...
Idelalisib Toxicities Appear to Be Immune-Related
Phosphoinositide 3-kinase (PI3K) inhibitors represent a highly active class of drug for the treatment of chronic lymphocytic leukemia (CLL). Idelalisib (Zydelig), a PI3K-delta inhibitor and the first PI3K inhibitor to be approved by the U.S. Food and Drug Administration (FDA) for CLL, has...
Venetoclax Achieves Durable and Deep Remissions in CLL
Preliminary study results suggest that venetoclax (Venclexta) plus rituximab (Rituxan) is a highly active combination in relapsed/refractory chronic lymphocytic leukemia (CLL), achieving durable responses and minimal residual disease negativity in previously treated patients. “The results of our...
Expert Point of View: Manish Shah, MD and Daniel F. Hayes, MD, FACP, FASCO
Manish Shah, MD, Director of Gastrointestinal Oncology at NewYork-Presbyterian and Weill Cornell Medicine, was impressed with the findings of the two subanalyses of CALGB 89803. “The study found a 46% reduction in the risk of recurrence with two servings of tree nuts a week, and that’s more than ...
Tree Nut Consumption May Improve Outcomes in Stage III Colon Cancer
Tree nut consumption, as well as a generally healthy lifestyle, significantly reduced the risk of cancer recurrence and death in patients with stage III colon cancer treated in the Cancer and Leukemia Group B (CALGB) 89803 trial, researchers reported at the 2017 ASCO Annual Meeting. Two subanalyses ...
ASCO 2017: I-SPY 2 Trial: Combination of Pembrolizumab Plus Standard Neoadjuvant Therapy in High-Risk Breast Cancer
At the 2017 ASCO Annual Meeting, results were presented from the phase II I-SPY 2 trial investigating pembrolizumab (Keytruda) in combination with standard therapy (paclitaxel followed by doxorubicin and cyclophosphamide) as a neoadjuvant treatment for patients with locally advanced triple-negative ...
Making American Research Great Again
In the past 10 years, we have made remarkable advances in how we fight cancer. One of the most powerful new tools in our arsenal is cancer immunotherapy, which reawakens our own immune system to produce stunning results for many suffering from advanced cancer. Immunotherapy saved President Jimmy...
ASCO 2017: Ibrutinib Plus Cellular Therapy CTL119 May Lead to Complete Remissions in CLL
Combining the kinase inhibitor ibrutinib (Imbruvica) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University...
Value-Based Decision-Making Tools: The View Ahead
As new treatment decision-making tools make their way toward and into the clinic, oncologists are getting a sense of how they may affect clinical practice—and beginning to look farther down the road. “What do you see ahead for clinicians?” asked Christian Downs, JD, Executive Director of the...
ASCO Congratulates NIH Director Francis Collins on Remaining in Critical Leadership Position
ASCO President Bruce E. Johnson, MD, FASCO, released the following statement today: “ASCO congratulates Francis S. Collins, MD, PhD, on the announcement of his continued service as the Director of the National Institutes of Health (NIH). A renowned researcher and skilled administrator, Dr....
ALEX Trial: Alectinib vs Crizotinib in Untreated Advanced ALK-Positive NSCLC
As reported at the recent ASCO Annual Meeting and in The New England Journal of Medicine by Peters et al, the phase III ALEX trial has shown improvement in progression-free survival with alectinib (Alecensa) vs crizotinib (Xalkori) in the first-line treatment of advanced ALK-positive...
ASCO 2017: Higher Gut Bacteria Diversity Tied to Slower Metastatic Melanoma Progression
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, reported Wargo et al at the 2017 ASCO Annual Meeting (Abstract 3008). Their study of fecal samples from 105 patients treated with...
Expert Point of View: Trever Bivona, MD, PhD
“The results of this trial are promising but need to be reproduced in the United States and other countries before clear recommendations can be made. There are adjuvant studies such as ALCHEMIST underway to test this strategy in U.S. patients,” said Trever Bivona, MD, PhD, Associate Professor of...
Adjuvant Gefitinib Delays Recurrence in EGFR-Positive NSCLC
Adjuvant therapy with gefitinib (Iressa), an epidermal growth factor receptor (EGFR)-targeted agent, was more successful at preventing recurrence than standard-of-care chemotherapy, in a phase III study of patients with EGFR-positive non–small cell lung cancer (NSCLC).1 Gefitinib extended...
ASCO 2017: Adding PEGPH20 to Standard Treatment in Metastatic Pancreatic Cancer May Delay Disease Progression
By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a phase II clinical trial led by an...
ASCO 2017: Implementing Cost Transparency in Oncology
Being transparent about the cost of cancer treatments with patients has been increasingly recommended to help minimize financial harm and improve care, but what's preventing or derailing those conversations is less understood. New findings from Penn Medicine that identified several barriers and key ...
ASCO 2017: Many Emergency Department Visits Among Patients With Cancer Appear Preventable
Among patients with cancer, as many as 53% of emergency department visits that do not require admission could be avoided with better symptom management and greater availability of outpatient care tailored to their needs, according to a new study from Fred Hutchinson Cancer...
ASCO 2017: Impact of Patient Age on Molecular Alterations in Colorectal Tumors
Younger patients with colon cancer appear to have more than three times as many mutations in their tumors as older patients, which could lead to more effective treatment decisions, according to researchers at Georgetown Lombardi Comprehensive Cancer Center. In a new study, they found that tumor...
ASCO's TAPUR Study Continues Its Expansion of Sites, Participants, and Collaborators
ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility. “We are very pleased with the...
Dinutuximab vs Temsirolimus in Combination Therapy for Children With Refractory or Relapsed Neuroblastoma
A randomized phase II trial (Children’s Oncology Group [COG] ANBL1221) has resulted in the selection of dinutuximab (Unituxin) plus irinotecan/temozolomide as a regimen to be further evaluated in the treatment of pediatric patients with refractory or relapsed neuroblastoma. Study results were ...
T2:ERG and PCA3 RNA Urinary Testing for Detecting Aggressive Prostate Cancer
Combined testing for urinary PCA3 and TMPRSS2:ERG (T2:ERG) RNA may increase accuracy in identifying the risk for aggressive early prostate cancer, according to a study reported in JAMA Oncology by Sanda et al in the EDRN-PCA3 Study Group. Study Details The study involved 516 development cohort...
Effect of Previous Radiotherapy on Outcome With Pembrolizumab in NSCLC
In a single-site experience reported in The Lancet Oncology by Shaverdian et al, patients with advanced non–small cell lung cancer (NSCLC) in the phase I KEYNOTE-001 trial of pembrolizumab (Keytruda) were found to have better outcomes if they had received prior radiotherapy. Study Details...
Daniel Heng, MD, MPH, and Sumanta K. Pal, MD, on Renal Cell Carcinoma: Expert Perspectives
Daniel Heng, MD, MPH, of the Tom Baker Cancer Centre and the University of Calgary, and Sumanta K. Pal, MD, of the City of Hope, discuss key findings presented at ASCO: adjuvant pazopanib vs placebo after nephrectomy in patients with locally advanced disease (the PROTECT Trial), and adjuvant...
Toni K. Choueiri, MD, and Sumanta K. Pal, MD, on Top Kidney Cancer Abstracts: Expert Perspectives
Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, exchange views on the key papers in renal cell carcinoma presented at ASCO’s 2017 nonprostate GU oral abstract session. (Abstracts 4504, 4505, 4506, 4507, 4508)
ASCO 2017: Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer
Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non–small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa), one of the standard targeted...
ASCO 2017: Early Research Suggests First Immunotherapy for Mesothelioma on the Horizon
Malignant pleural mesothelioma is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13 to 15 months. All patients relapse despite initial chemotherapy, more than 50% of them within 6 months...
ASCO 2017: BCMA-Specific CAR T-Cell Therapy Sends Relapsed/Refractory Multiple Myeloma Into Lasting Remission in an Early Trial
In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving immunotherapy with chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein, or BCMA. Most patients had only mild side effects. The study was presented by Fan et al...
